Table 2 Patterns of Care by Sex
From: Overactive bladder in an integrated delivery system: a longitudinal cohort study
Characteristic | Overall (n = 7362) | Female (n = 5417) | Male (n = 1945) | P value |
|---|---|---|---|---|
No. (column %) | ||||
Source of care | ||||
Co-managed* | 1828 (25) | 1366 (25) | 462 (24) | < .001 |
PCP only† | 1288 (17) | 1021 (19) | 267 (14) | |
Urologist only‡ | 938 (13) | 374 (7) | 564 (29) | |
Gynecologist only§ | 195 (3) | 195 (4) | 0 (0) | |
Urogynecologist only║ | 76 (1) | 76 (1) | 0 (0) | |
Urologist, gynecologist, and/or urogynecologist only¶ | 637 (9) | 633 (12) | 4 (0) | |
Other# | 2400 (33) | 1752 (32) | 648 (33) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |
Initial medication | ||||
Darifenacin | 100 (1) | 75 (1) | 25 (1) | .006 |
Fesoterodine | 55 (1) | 41 (1) | 14 (1) | |
Flavoxate | 9 (0) | 9 (0) | 0 (0) | |
Hyoscyamine | 83 (1) | 65 (1) | 18 (1) | |
Imipramine | 133 (2) | 103 (2) | 30 (2) | |
Mirabegron | 27 (0) | 20 (0) | 7 (0) | |
Oxybutynin | 1545 (21) | 1184 (22) | 361 (19) | |
Solifenacin | 428 (6) | 324 (6) | 104 (5) | |
Tolterodine | 485 (7) | 359 (7) | 126 (6) | |
Trospium | 91 (1) | 75 (1) | 16 (1) | |
None | 4406 (60) | 3162 (58) | 1244 (64) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |
Treatment | ||||
Biofeedback | 10 (0) | 9 (0) | 1 (0) | .24 |
No biofeedback | 7352 (100) | 5408 (100) | 1944 (100) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |
OnabotulinumtoxinA | 171 (2) | 131 (2) | 40 (2) | .36 |
No onabotulinumtoxinA | 7191 (98) | 5286 (98) | 1905 (98) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |
Sacral nerve stimulation | 74 (1) | 56 (1) | 18 (1) | .68 |
No sacral nerve stimulation | 7288 (99) | 5361 (99) | 1927 (99) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |
Bladder augmentation | 0 (0) | 0 (0) | 0 (0) | NA |
No bladder augmentation | 7362 (100) | 5417 (100) | 1945 (100) | |
Total | 7362 (100) | 5417 (100) | 1945 (100) | |